home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410b.zip
/
M94A0280.TXT
< prev
next >
Wrap
Text File
|
1994-10-08
|
2KB
|
40 lines
Document 0280
DOCN M94A0280
TI Clinical and immunologic evaluation of HIV-infected patients treated
with dinitrochlorobenzene.
DT 9412
AU Stricker RB; Elswood BF; Goldberg B; Dumlao C; Van Elk J; Henry J;
Winger EE; Epstein WL; HemaCare Corporation, San Francisco, CA 94108.
SO J Am Acad Dermatol. 1994 Sep;31(3 Pt 1):462-6. Unique Identifier :
AIDSLINE MED/94358210
AB BACKGROUND: Promotion of cell-mediated immunity appears to be an
important goal in the control of HIV infection. Topical
dinitrochlorobenzene (DNCB) stimulates systemic cell-mediated immunity
via the induction of cutaneous delayed-type hypersensitivity. OBJECTIVE:
Our goal was to evaluate the clinical and immunologic effects of chronic
DNCB application in a group of 24 HIV-infected patients. METHODS: We
observed the patients for a mean of 28 months (range, 14 to 44 months).
Of the 24 patients, 13 continued weekly DNCB application throughout the
study (the compliant group), and 11 discontinued DNCB use after a mean
of 10.9 months (the noncompliant group). RESULTS: Two of the 13
compliant patients progressed to AIDS; none of these patients died. In
contrast, AIDS developed in 5 of the 11 noncompliant patients and four
of these patients died. Analysis of lymphocyte subsets revealed
significant increases in natural killer cells and activated/cytotoxic
CD8 T-cell subsets in the compliant group. In contrast, these cellular
immune-related lymphocyte subsets decreased in the noncompliant
subjects. Although CD4 T-cell levels decreased in both groups, there was
a significantly greater drop in the noncompliant patients. CD8+CD38+ T
cells increased significantly in both groups. CONCLUSION: Chronic DNCB
application appears to have a beneficial clinical and immunomodulatory
effect in HIV-infected patients.
DE Acquired Immunodeficiency Syndrome/IMMUNOLOGY Antigens, CD/ANALYSIS
CD4-CD8 Ratio Dinitrochlorobenzene/*THERAPEUTIC USE Flow Cytometry
Human HIV Infections/DRUG THERAPY/*IMMUNOLOGY Immunity, Cellular
Lymphocyte Subsets Male Patient Compliance Support, Non-U.S. Gov't
JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).